Read the full article here.
This content was originally published by McKinsey Insights & Publications. Original publishers retain all rights. It appears here for a limited time before automated archiving. By McKinsey Insights & Publications
Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment opportunities and entry strategies will help guide their portfolio decisions.